Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christodoulos Papadopoulos

Showing results (61-70 of 127) with videos related to

Pageof 13
Sort By:
The American Journal of Cardiology|September 9, 2021
Updated Meta-Analysis of Cardiovascular Outcome Trials Evaluating Cardiovascular Efficacy of Glucagon-Like Peptide-1 Receptor AgonistsDimitrios Patoulias, Christodoulos Papadopoulos, George Kassimis, et al.
The American Journal of Cardiology|April 9, 2022
Meta-Analysis Evaluating the Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors in Patients With Acute or Recently Decompensated Heart FailureDimitrios Patoulias, Michael Doumas, George Kassimis, et al.
ESC Heart Failure|December 21, 2019
Time to assess the effects of sodium-glucose co-transporter-2 inhibitors on the 'forgotten' right ventricle?Dimitrios Patoulias, Alexandra Katsimardou, Maria Toumpourleka, et al.
Journal of Diabetes and Metabolic Disorders|June 8, 2022
Net benefit regarding the risk for death with sodium-glucose co-transporter-2 inhibitors across the hallmark cardiovascular and renal outcome trials; are there any drug differences?Dimitrios Patoulias, Christodoulos Papadopoulos, Aristi Boulmpou, et al.
The American Journal of Cardiology|May 22, 2022
Meta-Analysis Assessing the Cardiovascular Safety of Semaglutide for the Treatment of Overweight or ObesityDimitrios Patoulias, Christodoulos Papadopoulos, George Kassimis, et al.
Polish Archives of Internal Medicine|March 30, 2021
The obesity pandemic among patients with coronary artery disease: do we have enough to tackle its progression?Dimitrios Patoulias, Fotios Siskos, Aristi Boulmpou, et al.
The American Journal of Cardiology|October 12, 2020
Updated Meta-Analysis of Trials Assessing the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Black PatientsDimitrios Patoulias, Christodoulos Papadopoulos, Konstantinos Stavropoulos, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|October 14, 2020
Sodium-Glucose Cotransporter 2 Inhibitors and Major COVID-19 Outcomes: Promising Mechanisms, Conflicting Data, and Intriguing Clinical DecisionsDimitrios Patoulias, Christodoulos Papadopoulos, Alexandra Katsimardou, et al.
Polish Archives of Internal Medicine|October 29, 2020
Use of corticosteroids in SARS-CoV-2 infection: foe, or can they become a friend?Dimitrios Patoulias, Christodoulos Papadopoulos, Alexandra Katsimardou, et al.
Acta Diabetologica|August 19, 2022
Effect of SGLT-2 inhibitors on cardiac autonomic function in type 2 diabetes mellitus: a meta-analysis of randomized controlled trialsDimitrios Patoulias, Alexandra Katsimardou, Nikolaos Fragakis, et al.
Pageof 13

Showing results (61-70 of 127) with videos related to

Sort By:
Pageof 13
The American Journal of Cardiology|September 9, 2021
Updated Meta-Analysis of Cardiovascular Outcome Trials Evaluating Cardiovascular Efficacy of Glucagon-Like Peptide-1 Receptor AgonistsDimitrios Patoulias, Christodoulos Papadopoulos, George Kassimis, et al.
The American Journal of Cardiology|April 9, 2022
Meta-Analysis Evaluating the Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors in Patients With Acute or Recently Decompensated Heart FailureDimitrios Patoulias, Michael Doumas, George Kassimis, et al.
ESC Heart Failure|December 21, 2019
Time to assess the effects of sodium-glucose co-transporter-2 inhibitors on the 'forgotten' right ventricle?Dimitrios Patoulias, Alexandra Katsimardou, Maria Toumpourleka, et al.
Journal of Diabetes and Metabolic Disorders|June 8, 2022
Net benefit regarding the risk for death with sodium-glucose co-transporter-2 inhibitors across the hallmark cardiovascular and renal outcome trials; are there any drug differences?Dimitrios Patoulias, Christodoulos Papadopoulos, Aristi Boulmpou, et al.
The American Journal of Cardiology|May 22, 2022
Meta-Analysis Assessing the Cardiovascular Safety of Semaglutide for the Treatment of Overweight or ObesityDimitrios Patoulias, Christodoulos Papadopoulos, George Kassimis, et al.
Polish Archives of Internal Medicine|March 30, 2021
The obesity pandemic among patients with coronary artery disease: do we have enough to tackle its progression?Dimitrios Patoulias, Fotios Siskos, Aristi Boulmpou, et al.
The American Journal of Cardiology|October 12, 2020
Updated Meta-Analysis of Trials Assessing the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Black PatientsDimitrios Patoulias, Christodoulos Papadopoulos, Konstantinos Stavropoulos, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|October 14, 2020
Sodium-Glucose Cotransporter 2 Inhibitors and Major COVID-19 Outcomes: Promising Mechanisms, Conflicting Data, and Intriguing Clinical DecisionsDimitrios Patoulias, Christodoulos Papadopoulos, Alexandra Katsimardou, et al.
Polish Archives of Internal Medicine|October 29, 2020
Use of corticosteroids in SARS-CoV-2 infection: foe, or can they become a friend?Dimitrios Patoulias, Christodoulos Papadopoulos, Alexandra Katsimardou, et al.
Acta Diabetologica|August 19, 2022
Effect of SGLT-2 inhibitors on cardiac autonomic function in type 2 diabetes mellitus: a meta-analysis of randomized controlled trialsDimitrios Patoulias, Alexandra Katsimardou, Nikolaos Fragakis, et al.
Pageof 13